Latest Articles
-
What’s Happening With Cisco’s Stock?
Note: Cisco’s FY 2024 ended July 27, 2024 Cisco Systems Inc (NASDAQ: CSCO), a company providing networking equipment, security, collaboration, and cloud management services, grew marginally by 0.8% on Wednesday, 13th November to $59, as ...
-
What’s Next For Halliburton?
After a 15% decline since the beginning of the year, at the current price of around $30 per share, we believe Halliburton stock (NYSE: HAL), an energy company organized into the exploration, development, and production of oil and natural gas ...
-
Should You Pick Electronic Arts Stock At $165?
Electronic Arts (NYSE: EA) has risen over 25% from levels of $130 in early 2022 to $160 now, aligning with the performance of the S&P 500 index over this period. The company has seen a solid sales growth over the recent years, despite tepi...
-
Pick Google Over Amazon?
We believe that Alphabet (NASDAQ: GOOG) is currently a better pick over Amazon stock (NASDAQ:AMZN). GOOG stock trades at 22x forward earnings, versus 42x for AMZN. We think this gap in valuation will narrow in favor of Google in the coming ye...
-
Up 70% This Year, Is Netflix Stock Worth The Risk?
Netflix (NASDAQ:NFLX) stock has had a solid year, rising by almost 72% in year-to-date trading. The company successfully navigated a brief subscriber decline post-Covid-19. The stock now trades at almost $840 per share led by the company’s ...
-
What Should Investors Do If Super Micro Stock Is Delisted?
Super Micro Computer stock (NASDAQ: SMCI) is seeing a real possibility of being delisted from the Nasdaq in the coming days. The company faces a November 16th deadline to either file its delayed 10-K annual report or submit a plan with the SEC to...
-
What’s Next For Home Depot Stock After An Upbeat Q3?
Note: Home Depot FY’23 ended on January 28, 2024. Home Depot stock (NYSE: HD), the world’s largest home improvement retailer, fell marginally 1.3% on Tuesday, 12th November (to $403), as compared to a 0.3% decline in the S&P 500 ...
-
Why Did United States Steel Stock Drop?
United States Steel stock (NYSE:X) dropped nearly 6% during Wednesday’s trading, accelerating the losing streak from the past week. Nippon Steel Corporation, Japan’s largest steelmaker, set out to acquire United States Steel in December 202...
-
Why Goldman Stock Is Up 57% This Year
Goldman Sachs’ stock (NYSE: GS) has had a very good year, rising by a solid 57% year-to-date. In comparison, its peer Morgan Stanley (NYSE: MS) has seen its stock rise 41% over the same period. Some of the stock’s recent gains come off...
-
What’s Behind The 50% Rise In Amgen Stock?
Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone density, which could be a potential safety risk. Mari...
-
Should You Pick SNAP Stock At $11?
Snap’s stock (NYSE: SNAP) was down 6% on Tuesday, November 12, after a media report emerged stating that the Trump administration is expected to attempt to halt a possible U.S. ban on TikTok next year. TikTok owner ByteDance was given a deadlin...
-
Delisting Deadline Looms For Super Micro Stock
Super Micro Computer stock (NASDAQ: SMCI) fell by about 6% in Tuesday’s trading and remains down 54% over the past month amid significant corporate governance concerns and questions about the company’s financial reporting. Hindenburg ...
-
Trump Boosts Tesla, But Risks Loom
Tesla (NASDAQ:TSLA) stock gained 9% in Monday’s trading, closing at about $350 per share. The stock has been up almost 40% since November 5th, the day of the presidential election. Tesla stock now trades at levels last seen around early 202...
-
AbbVie’s Pain Is BMY’s Gain
Bristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November 11, after its peer AbbVie (NYSE; ABBV) announced that two of its mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal....
-
What’s Happening With AbbVie Stock?
AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. Emraclidine was developed by Cerevel...
